Chemomab’s CM-101 Shows Promise in PSC Trial
Company Announcements

Chemomab’s CM-101 Shows Promise in PSC Trial

Chemomab Therapeutics (CMMB) has released an update.

Chemomab Therapeutics has reported encouraging outcomes from a Phase 2 trial of CM-101, showcasing significant improvements in primary sclerosing cholangitis (PSC) symptoms, with positive effects on liver stiffness, bilirubin levels, and pruritis. The trial results, demonstrating CM-101’s safety and potential as a disease-modifying treatment, set the stage for a Phase 3 trial following discussions with the FDA. These developments indicate a promising horizon for PSC treatment, a condition currently lacking approved therapies.

For further insights into CMMB stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskChemomab’s Positive Trial Results Boost Investor Confidence
TheFlyChemomab Therapeutics reports Q3 EPS (1c) vs (2c) last year
TheFlyChemomab Therapeutics sees cash runway through beginning of 2026
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App